An anonymous reader writes "A Newtown couple, both scientists, who lost their daughter in the school shooting, are wondering whether there were clues in the shooter's physiological makeup — his DNA, his blood, his brain chemistry. They are now involved in a search for biomarkers, similar to those that may indicate disease, for violence. They are raising money to help fund this research, but the effort is running into obstacles, in part, over ethical concerns. 'I'm not opposed to research on violence and biomarkers, but I'm concerned about making too big of a leap between biomarkers and violence,' said Troy Duster, a researcher at the University of California at Berkeley. There is concern that science may find biomarkers long before society can deal with its implications."

aarondubrow writes "Researchers reported results in Nature Communications on a new way of sculpting tailor-made fluid flows by placing tiny pillars in microfluidic channels [abstract; article is paywalled]. The method could allow clinicians to better separate white blood cells in a sample, increase mixing in industrial applications, and more quickly perform lab-on-a-chip-type operation. Using the Ranger and Stampede supercomputers, the researchers ran more than 1,000 simulations representing combinations of speeds, thicknesses, heights or offsets that produce unique flows. This library of transformations will help the broader community design and use sculpted fluid flows."

HonorPoncaCityDotCom writes "For all the wonders of fresh broccoli, in most parts of the country it is only available from local growers during the cooler weeks at either end of the growing season, nowhere near long enough to become a fixture in grocery stores or kitchens. But now Michael Moss writes in the NY Times that Thomas Bjorkman is out to change all that by creating a new version of the plant that can thrive in hot, steamy summers like those in New York, South Carolina or Iowa and is easy and inexpensive enough to grow in large volumes. And Bjorkman's quest doesn't stop there: His crucifer is also crisp, subtly sweet and utterly tender when eaten fresh-picked and aims to maximize the concentration of glucoraphanin, a mildly toxic compound used by plants to fight insects that in humans may stimulate our bodies' natural chemical defenses to aid in preventing cancer and warding off heart disease. The Eastern Broccoli Project's goal is to create a regional food network for an increasingly important and nutritious vegetable that may serve as a model network for other specialty crops to help shift American attitudes toward fruits and vegetables by increasing their allure and usefulness in cooking, while increasing their nutritional loads. 'If you've had really fresh broccoli, you know it's an entirely different thing,' says Bjorkman, a plant scientist at Cornell University. 'And if the health-policy goal is to vastly increase the consumption of broccoli, then we need a ready supply, at an attractive price.'"

Ogi_UnixNut writes "Scientists in Japan have succeeded in cloning a mouse from a drop of blood. From the BBC: 'Circulating blood cells collected from the tail of a donor mouse were used to produce the clone, a team at the Riken BioResource Center reports in the journal Biology of Reproduction.' The female mouse managed to live a normal lifespan and could reproduce, according to the researchers."

the_newsbeagle writes "Fast, cheap genetic sequencing machines have the potential to revolutionize science and medicine--but only if geneticists can figure out how to deal with the floods of data their machines are producing. That's where computer scientists can save the day. In this article from IEEE Spectrum, two computational biologists explain how they're borrowing big data solutions from companies like Google and Amazon to meet the challenge. An explanation of the scope of the problem, from the article: 'The roughly 2000 sequencing instruments in labs and hospitals around the world can collectively generate about 15 petabytes of compressed genetic data each year. To put this into perspective, if you were to write this data onto standard DVDs, the resulting stack would be more than 2 miles tall. And with sequencing capacity increasing at a rate of around three- to fivefold per year, next year the stack would be around 6 to 10 miles tall. At this rate, within the next five years the stack of DVDs could reach higher than the orbit of the International Space Station.'"

First time accepted submitter bmahersciwriter writes "Hugh Rienhoff has searched for more than a decade for the cause of a mysterious constellation of clinical features in his daugther Bea: skinny legs, curled fingers and always the specter that she might have a high risk of cardiovascular complications. He even bought second hand lab equipment to prepare some of her genes for sequencing in his basement. Now, he has an answer."

sciencehabit writes "Scientists have sequenced the oldest genome to date—and shaken up the horse family tree in the process. Ancient DNA derived from a horse fossil that's between 560,000 and 780,000 years old suggests that all living equids—members of the family that includes horses, donkeys, and zebras—shared a common ancestor that lived at least 4 million years ago, approximately 2 million years earlier than most previous estimates. The discovery offers new insights into equine evolution and raises the prospect of recovering and exploring older DNA than previously thought possible."

An anonymous reader writes "An NJIT research professor known for his cutting-edge work with carbon nanotubes is overseeing the manufacture of a prototype lab-on-a-chip that would someday enable a physician to detect disease or virus from just one drop of liquid, including blood. 'Scalable nano-bioprobes with sub-cellular resolution for cell detection,' (Elsevier, Vol. 45), which will publish on July 15, 2013 but is available now online, describes how NJIT research professors Reginald Farrow and Alokik Kanwal, his former postdoctoral fellow, and their team have created a carbon nanotube-based device to noninvasively and quickly detect mobile single cells with the potential to maintain a high degree of spatial resolution."

First time accepted submitter overmod writes "Browsing on a completely unrelated subject, I came across this New York Times description of Solazyme. From the article: '...in 2003, Mr. Wolfson packed up and moved from New York to Palo Alto, Calif., where Mr. Dillon lived. They started a company called Solazyme. In mythical Valley tradition, they worked in Mr. Dillon’s garage, growing algae in test tubes. And they found a small knot of investors attracted by the prospect of compressing a multimillion-year process into a matter of days. Now, a decade later, they have released into the marketplace their very first algae-derived oil produced at a commercial scale. Yet the destination for this oil — pale, odorless and dispensed from a small matte-gold bottle with an eyedropper — is not gas tanks, but the faces of women worried about their aging skin.' What I find interesting is the model they've adopted for short-term growth, which I would not have seen coming from a technology oriented toward biofuel production. Leads me to wonder what other nominally-green technologies that would otherwise be slow if not impossible to scale to workable businesses might have 'niche' applications, with high perceived marginal value, that could be used to boost capital, rather than relying on donations, grants, or nebulous save-the-planet goodwill."

MTorrice writes "Crab shells usually are just a nuisance that you have to crack and dig through to get the delicious meat inside. But one team of materials scientists thinks the shells could help them fabricate materials for long lasting batteries. The team used the nanostructures (abstract) found in the crustacean shells as templates to make sulfur and silicon electrode materials for lithium-ion batteries. Sulfur or silicon electrodes have a 10-times greater theoretical energy storage capacity than electrodes used in commercial batteries."

sfcrazy writes "A top Monsanto executive has won the prestigious World Food Prize. Secretary of State John Kerry announced the award where Robert T. Fraley, the executive vice president and CTO of Monsanto, won the prize along with two other scientists from Belgium and the US. The award was given for devising a method to insert genes from another organism into plant cells, which could produce new genetic lines with highly favorable traits."

Zothecula writes "Applied DNA Sciences (ADNAS) has developed a new approach to solve crimes using DNA tagging. The difference is that instead of tagging the objects being stolen, the company's system tags the perpetrator with DNA. While this has been tried before by applying the DNA to a fleeing criminal with a gun, ADNAS has adopted a more subtle approach."

ColdWetDog writes "The ongoing story of Myriad Genetics versus the rest of the world has come to an end. In a 9-0 decision, the US Supreme Court has decided that human genes cannot be patented. From a brief Bloomberg article: 'Writing for the court, Justice Clarence Thomas said isolated DNA is a "product of nature and not patent eligible merely because it has been isolated." At the same time, Thomas said synthetic molecules known as complementary DNA, or cDNA, can be patented because they require a significant amount of human manipulation to create.' Seems perfectly sane. Raw genes, the ones you find in nature are, wait for it — natural. Other bits of manipulated DNA / RNA / protein which take skill and time to create are potentially patentable. Oddly, Myriad Genetics stock actually rose on that information." Adds reader the eric conspiracy: "The result for Myriad is that they still have protection for their test, however the decision also allows researchers to work with the DNA sequences that are predecessors to the cDNA used in the test." Here's an AP report on the ruling, as carried by the Washington Post.

sciencehabit writes "Despite a slow economy, business in genomics has boomed and has directly and indirectly boosted the U.S. economy by $965 billion since 1988, according to a new study (pdf). In 2012 alone, genomics-related research and development, along with relevant industry activities, contributed $31 billion to the U.S. gross national product and helped support 152,000 jobs, the biomedical funding advocacy group United for Medical Research announced today in Washington, D.C. Based on total U.S. spending, the country gets $65 back for every $1 it spends on the field."

This is our second video starring Backyard Brains (Motto: "Neuroscience for Everyone!"). The first one was pretty lab-oriented, with a twitching roach leg here and there. This one has more roaches, with most of them crawling on command. Will the DoD see this and decide to make cockroach soldiers? Or roboroach bomb detectors and defusers? Or cockroach drone pilots? Anything's possible these days. But meanwhile, relax and enjoy learning about roboroaches and watching how, with little circuit boards on their little backs, they scurry hither and yon under control of their human masters. WARNING: Excessively squeamish people should not watch this video, but should stick to the transcript.

MTorrice writes "Men's options for birth control have significant downsides: Condoms are not as effective as hormonal methods for women, and vasectomies require surgery and are irreversible. Doctors and scientists have for decades searched for more effective and desirable male contraception techniques. Researchers in China now propose a nonsurgical, reversible, and low-cost method. They show that infrared laser light heats up gold nanorods injected into mice testes, leading to reduced fertility (abstract) in the animals."

Nerval's Lobster writes "Monsanto is more infamous for growing its genetically modified crops than its use of software, but a series of corporate acquisitions and a new emphasis on tech solutions has transformed it into a firm that acts more like an innovative IT vendor than an agribusiness giant. Jim McCarter (the Entrepreneur in Residence for Monsanto) recently detailed for an audience in St. Louis how the company's IT efforts are expanding. Monsanto's core projects generate huge amounts of bits, especially its genomic efforts, which are the focus of so much public attention. Other big data gobblers are the phenotypes of millions of DNA structures that describe the various biological properties of each plant, and the photographic imagery of crop fields. (All told, there are several tens of petabytes that need storage and analysis, a number that's doubling roughly every 16 months.) With all that tech muscle, the company has launched IT-based initiatives such as its FieldScripts software, which uses proprietary algorithms (fed with data from the FieldScripts Testing Network and Monsanto research) to recommend where to best plant corn hybrids. 'Just like Amazon has its recommendation engine for what book to buy, we will have our recommendations of what and how a grower should plant a particular crop,' said McCarter. 'All fields aren't uniform and shouldn't be planted uniformly either.' Despite its increasingly sophisticated use of data analytics in the name of greater crop yields, however, Monsanto faces pushback from various groups with an aversion to genetically modified food; a current ballot initiative in Washington State, for example, could result in genetically modified foods needing a label in order to go on sale here. The company has also inspired a 'March Against Monsanto,' which has been much in the news lately."

adeelarshad82 writes "Researchers at the University of Illinois at Urbana-Champaign (UIUC) have determined the precise chemical structure of the HIV 'capsid,' a protein shell that protects the virus's genetic material and is a key to its virulence. The experiment involved mapping an incredible 64 million atoms to simulate the HIV capsid, pictured here. Interestingly no current HIV drugs target the HIV capsid and researchers believe that understanding the structure of the HIV capsid may hold the key to the development of new and more effective antiretroviral drugs. What makes this whole experiment even more fascinating is the use of Blue Waters, a Cray XK7 supercomputer with 3,000 Nvidia Tesla K20X GPU accelerators."

A virus that has so far killed nearly thirty people in seven countries faces a non-medical obstacle to treatment: Patents. Reader Presto Vivace writes with this excerpt from the Council on Foreign Relations: "At the center of the dispute is a Dutch laboratory that claims all rights to the genetic sequence of the Middle East Respiratory Syndrome coronavirus [MERS-CoV]. Saudi Arabia's deputy health minister, Ziad Memish, told the WHO meeting that "someone"--a reference to Egyptian virologist Ali Zaki--mailed a sample of the new SARS-like virus out of his country without government consent in June 2012, giving it to Dutch virologist Ron Fouchier of Erasmus Medical Center in Rotterdam."

redletterdave writes "In trying to solve the 'mechanical mismatch' between humans and electronics — particularly wearables — special projects chief Regina Dugan unveiled two new projects currently in development at Google's Motorola Mobility centered on rethinking authentication methodology, including electronic tattoos and ingestible pills. Of the pill, which Dugan called her 'first superpower,' she described it as an 'inside-out potato battery' that when swallowed, the acids in one's stomach serve as the electrolyte to power an 18-bit ECG-like signal that essentially turns one's body into an authentication token. 'It means my arms are like wires and my hands are like alligator clips [so] when I touch my phone, my computer, my door, I'm authenticated,' Dugan said. 'This is not science fiction.'"